Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Observational study

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    409 result(s) found for: Observational study. Displaying page 2 of 21.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-001384-60 Sponsor Protocol Number: C2380329 Start Date*: 2005-07-14
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: An exploratory, observational cohort study investigating commercially available treatments which may reduce the scab stage of recurrent herpes labialis
    Medical condition: Recurrent herpes labialis (RHL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004622-18 Sponsor Protocol Number: BAYO9867/100201 Start Date*: 2015-01-12
    Sponsor Name:Bayer HealthCare AG
    Full Title: A prospective, open-label, non-randomized, naturalistic, long-term safety surveillance, observational study of either ciprofloxacin (either as oral suspension, oral tablets or sequential IV followe...
    Medical condition: Infectious Diseases
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-000842-16 Sponsor Protocol Number: PIRVACoV Start Date*: 2021-03-18
    Sponsor Name:Kristina Jakobsson
    Full Title: Does PFAS-exposure modify the risk of COVID-19 infection or the immunological response after vaccination against SARS-CoV-2?
    Medical condition: An observational study in healthy, differently PFAS-exposed subjects to check if PFAS modifies the immunological response to SARS-CoV-2 vaccination. The immunological response is quantified as SARS...
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004865 10084462 SARS-CoV-2 vaccination LLT
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002945-36 Sponsor Protocol Number: TRA108132 Start Date*: 2007-03-12
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: LENS – Long-term Eltrombopag ObservatioNal Study - A long term observational ocular safety study in adults who have received study medication (SB-497115-GR / eltrombopag olamine or placebo) in a ph...
    Medical condition: Long-term ocular safety specifically related to cataract formation in subjects who have previously participated in a phase II or III protocol for eltrombopag (SB-497715-GR)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10007739 Cataract LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) ES (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002118-39 Sponsor Protocol Number: 0000-027-00 Start Date*: 2005-07-12
    Sponsor Name:Merck & Co., Inc.
    Full Title: RECAP-DM (Real-life Effectiveness and Care Patterns of Diabetes Management)
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    7.0 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-004898-41 Sponsor Protocol Number: NBK241/1/2020 Start Date*: 2021-03-31
    Sponsor Name:MEDICAL UNIVERSITY OF GDAŃSK
    Full Title: A multicentre, parallel group, randomised, double blind, placebo-controlled, phase II study evaluating the efficacy and safety of reperfusion thrombolytic therapy with intravenous recombinant tissu...
    Medical condition: Acute ischemic stroke
    Disease: Version SOC Term Classification Code Term Level
    22.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001074-29 Sponsor Protocol Number: CLOU064A2201E1 Start Date*: 2019-10-10
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, multicenter, extension study to evaluate the long-term safety and tolerability of LOU064 in eligible subjects with CSU who have participated in CLOU064A2201
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) SK (Completed) FR (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-004953-26 Sponsor Protocol Number: BHS-TC13 Start Date*: 2016-03-11
    Sponsor Name:Ghent University Hospital
    Full Title: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.
    Medical condition: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003581-40 Sponsor Protocol Number: CRO1992 Start Date*: 2012-09-28
    Sponsor Name:Imperial College, Research Governance Manager
    Full Title: A prospective, observational study to examine the effects of ageing on the clinical outcomes of people living with HIV in England and Ireland.
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10000807 Acute HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004588-19 Sponsor Protocol Number: ESKETINTRD3005 Start Date*: 2015-08-04
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects with Tre...
    Medical condition: Treatment-resistant Major Depression
    Disease: Version SOC Term Classification Code Term Level
    18.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) ES (Completed) GB (Completed) LT (Completed) FI (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001526-26 Sponsor Protocol Number: 083 Start Date*: 2013-10-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: An Observational Follow-Up Study for: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporo...
    Medical condition: Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10028395 - Musculoskeletal and connective tissue disorders 10031282 Osteoporosis PT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Completed) LT (Completed) DE (Completed) EE (Completed) LV (Completed) ES (Completed) CZ (Completed) PL (Completed) BG (Completed) DK (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-000604-41 Sponsor Protocol Number: VX12-809-105 Start Date*: 2014-01-21
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygo...
    Medical condition: Cystic fibrosis in patients homozygous or heterozygous for the F508del-CFTR Mutation
    Disease: Version SOC Term Classification Code Term Level
    16.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) CZ (Completed) SE (Completed) AT (Completed) BE (Completed) GB (Completed) DE (Completed) NL (Completed) ES (Completed) IE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-005189-75 Sponsor Protocol Number: BO39633 Start Date*: 2017-07-13
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, MULTICENTER EXTENSION AND LONG-TERM OBSERVATIONAL STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH- AND/OR F. HOFFMANN LA ROCHE LTD-SPONSORED ATEZOLIZUMAB STUDY
    Medical condition: Cancer (Future parent protocols may include other cancer that are not included in this section)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046721 Urothelial carcinoma bladder stage III LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029514 Non-small cell lung cancer NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Trial now transitioned) BE (Completed) FR (Trial now transitioned) NL (Ongoing) SI (Completed) PT (Completed) DE (Completed) LV (Prematurely Ended) LT (Ongoing) SK (Prematurely Ended) BG (Completed) IT (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001379-21 Sponsor Protocol Number: VX15-770-126 Start Date*: 2017-08-01
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Init...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000447-26 Sponsor Protocol Number: SPK-8011-301 Start Date*: 2019-10-23
    Sponsor Name:Spark Therapeutics, Inc
    Full Title: An Open-label, Non-investigational Product, Multi-center, Lead-in Study to Evaluate Prospective Bleeding and Infusion Data of Current FVIII Replacement Therapy in Adult Males with Hemophilia A
    Medical condition: Hemophilia A
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005636-29 Sponsor Protocol Number: IDX-03YF Start Date*: 2013-05-17
    Sponsor Name:Idenix Pharmaceuticals, Inc.
    Full Title: 3-Year, Observational Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Act...
    Medical condition: Chronic Hepatitis C Infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002083-13 Sponsor Protocol Number: HPVfollowup Start Date*: 2016-07-21
    Sponsor Name:Public Health England
    Full Title: An observational follow up study of a randomised parallel group phase IV study to evaluate the duration of the immune response to vaccine and non-vaccine HPV types in UK adolescent females who rece...
    Medical condition: No specific medical condition - immune reponses to HPV vaccination.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10071146 Human papilloma virus immunisation PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-003588-55 Sponsor Protocol Number: 20221102 Start Date*: 2024-10-14
    Sponsor Name:Isala
    Full Title: Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study
    Medical condition: Oncology
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-000454-12 Sponsor Protocol Number: P05315 Start Date*: 2009-03-03
    Sponsor Name:Schering Plough Research Institute, a Division of Schering Corporation
    Full Title: A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis.
    Medical condition: Moderate to severe plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    11.0 10037153 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Prematurely Ended) DK (Completed) HU (Prematurely Ended) FR (Prematurely Ended) GR (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019372-72 Sponsor Protocol Number: MV22970 Start Date*: 2010-04-16
    Sponsor Name:Pharmahungary Group
    Full Title: An Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza during Lactation.
    Medical condition: Lactating women who present with clinical symptoms indicative of influenza will be recruited to receive immediate treatment with oseltamivir at a standard dose of 75 mg twice daily. These subjects ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022000 Influenza LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 06:47:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA